Objective: In the present study, Lactobacillus johnsonii (La1) doubly labelled with 15 N and 13 C (dlLa1) was used to follow the metabolic fate of orally administered dlLa1 in humans. Design: Experimental study. Setting: Research Laboratory, Children's Hospital, University of Rostock. Subjects: A total of 10 healthy adults aged 23-36 y. Intervention: The subjects received 87 mg/kg body weight viable dlLa1 and 10 g raffinose together with breakfast. Expired air samples were taken over 14 h, whereas urine and faeces were collected over 2 days. A blood sample was taken after 2 h.
Introduction
The use of probiotics to enhance intestinal health has been proposed for many years. Metchnikoff (1845 Metchnikoff ( -1916 ) is one of the most famous and earliest propagators of the theory that ingestion of fermented foods, especially milk products, is connected to beneficial health effects (Alm, 1989) . Probiotics are traditionally defined as viable microorganisms that have beneficial effects in the prevention and treatment of specific pathologic conditions when they are ingested (Fuller, 1989; Lee & Salminen, 1995) . One of the important properties of probiotics is their ability to survive in the intestine (Kimoto et al, 2003) . Several studies have been published in recent years suggesting that probiotics can reinforce the intestinal mucosal barrier against deleterious agents (Fioramonti et al, 2003) . However, the scientific basis of the 'probiotic phenomenon' is currently under intensive scientific discussion and research. Owing to the potential health benefits, lactic acid bacteria are the most important bacteria of yoghurts. Lactobacilli belong to the Gram positive, nonspore-forming anaerobic rods. The organisms actively ferment carbohydrates as their main nutrition source and the primary metabolic end product of glucose fermentation is lactic acid (Kandler & Weiss, 1986) . Lactobacilli are prominent members of the microbiota. Lactobacillus johnsonii (La1), formerly known as L. acidophilus (Finegold et al, 1983 ) is a Lactobacillus strain of human origin that has been selected because of its ability to adhere to human intestinal mucosa (Bernet et al, 1994) . Human in vivo studies have proven that La1 supports the physiological function of the gastrointestinal tract (GIT) and stimulates the immune defense (Pfeiffer & Rosat, 1999) . The aim of the present study was to follow the metabolic fate of orally administered La1 labelled with 15 N and 13 C (doubly labelled La1, dlLa1) in humans.
Methods

Preparation of 15 N-yeast extract
The preparation of 15 N-labelled Saccharomyces cerevisiae yeast from 15 NH 4 Cl (99.0 at%, Campro Scientific, Berlin) as the sole nitrogen source has been previously described in detail (Wutzke et al, 1983 (Wutzke et al, , 1984 . In all, 25 g (wet weight) of 15 N-labelled yeast cells suspended in 100 ml distilled water were killed and hydrolysed by heating at 1001C for 45 min. The remaining cells were removed by centrifugation. The supernatant autoclaved at 1211C for 15 min was used as 15 N-yeast extract (Table 1) .
Culture of lactobacilli
La1 lactobacilli were obtained from 'Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH', Braunschweig, Germany. The organisms were inoculated into a de Man Rogosa Sharpe (MRS) broth and incubated at 371C for 24 h (De Man et al, 1960) . After incubation, 10 ml of lactobacillicontaining MRS broth were centrifuged at 4000 r.p.m. The resulting sediment suspended in 5 ml 0.9% NaCl solution was used as inoculum (5 Â 10 9 colony forming units
[CFU]) for 1000 ml of 15 N, 13 C-labelled Lactobacillus broth medium (Table 1) . After incubation at 371C for 72 h, the doubly labelled lactobacilli were separated from the culture medium by centrifugation at 4000 rpm and were purified by washing four times with 0.9% NaCl solution. Finally, the viable microorganisms were centrifuged at 14 000 rpm. The viable cell sediment covered with a sterile solution of 10 vol% glycerine in 0.9% NaCl was stored at À801C in a freezer. All ingredients except vitamins and ascorbic acid were autoclaved at 1211C for 15 min. Solutions of vitamins and ascorbic acid were sterilised separately by filtration. After mixture of the filtrated and autoclaved solutions, the medium was adjusted to pH 6.8 with 10% NaOH.
Subjects
A total of 10 healthy adults (eight female, two male, mean age: 25.9 y, mean body weight: 67.4 kg, mean body mass index: 23.4 kg/m 2 ) volunteered for this study. None of the subjects were receiving any medication or had had a history of gastrointestinal diseases. All subjects were in good health throughout the study and none of the subjects complained about any gastrointestinal problems.
The testing protocol was approved by the Committee on Ethics of the Faculty of Medicine of the University of Rostock.
Study protocols
Subjects were studied after an overnight fast. All volunteers received a continental breakfast made up of two wheat flour rolls, honey, and coffee beginning at 8:45. At 4 h after breakfast, all volunteers received an individually standardised regular lunch at 13:00. No other food was allowed until 4 h after breakfast. Baseline blood, breath, urine and faeces samples were collected at 8:30 30 min prior to the ingestion of both dlLa1 and raffinose to determine the baseline abundance of 13 C,
15
N and H 2 . During breakfast, dlLa1 and raffinose were administered simultaneously as a single oral pulse labelling at 9:00 in a dosage of 86.8 mg dlLa1 per kg body weight and 10 g raffinose per subject stirred in 125 g LC1 yoghurt (Nestlé AG).
Two expired breath samples obtained by direct exhalation into Exetainers TM were collected in 30 and 60-min intervals over a period of 14 h for measuring 13 CO 2 -enrichment (Radke et al, 1995; Wutzke et al, 1997; Leitzmann et al, 1998) . Additional breath samples were collected in 30 and 60 min-intervals over a period of 8 h by aspirating aliquots of end-expiratory air into 20 ml plastic syringes equipped with three-way stopcocks for measuring H 2 -concentration.
Urine was totally collected at 0.5, 1, 2, 4, 12 and 24-h intervals over a period of 48 h after dlLa1 administration. The urine fractions were pooled between the time intervals. Faeces scraped from polyvinyl film were also collected quantitatively over 2 days.
Sample preparation prior to isotope ratio mass spectrometry analysis Urine volumes and faecal masses were homogenised, recorded and 1 ml or 1 g, respectively, of each sample was stored at À201C until analysis (Wutzke et al, , 2001 ). After defrosting, 25 ml urine was transferred to tin boats, whereas 5 mg wet faeces were weighed on tin discs. All samples were dried at 601C for 2 h. Ammonia was separated in microdiffusion vessels by 12-h diffusion, following alkalisation of the urine with 6 N NaOH, and trapped in 0.1 M boric acid. This was followed by titration with 0.1 N HCl in the presence of Thashiro indicator (Faust et al, 1981; Wutzke et al, 1992) .
A blood sample was taken 2 h after dlLa1 administration at 11:00. After centrifugation of the citrated blood, the plasma was used for fibrinogen extraction with 0.5% CaCl 2 Á 6 H 2 O solution for 1 h at 371C (Faust et al, 1981) . For plasma protein precipitation, the remaining fibrinogen free plasma was treated with 1% Na 2 WO 4 Á H 2 O acidified with 1 N H 2 SO 4 . The soluble supernatant was removed by centrifugation at 4000 rpm (Faust et al, 1981) . Fibrinogen, plasma protein precipitation, and supernatant were stored at À201C until analysis. After defrosting 10 mg fibrinogen and plasma protein precipitate each, and 500 ml supernatant were transferred to tin boats. All samples were dried at 601C for 2 h.
Analytical techniques
Isotope ratio mass spectrometry. The 15 N-and 13 C-enrichments in dlLa1, fibrinogen, plasma protein, supernatant, urine, faeces, and breath were measured by isotope ratio mass spectrometry (Tracer mass 20-20, SerCon, Crewe, UK) as detailed previously (Barrie et al, 1989; Wutzke et al, 1997 Wutzke et al, , 2001 . The mass spectrometer 20-20 functions as a mass selective detector preset for three masses. A sector analyser is used with a triple Faraday collector and permanent magnet. A capillary interface is included for connecting to the automated breath carbon analysis (ABCA)-mode for gases and the automated nitrogen carbon analysis-solid liquid (ANCA-SL)-mode for solid samples. The precision (mean %RSD or CV) for 13 C and 15 N is 0.2% in the delta notation. An analytical grade urea standard (Serva Feinbiochemica GmbH, Heidelberg, Germany) calibrates both elemental composition and isotopic abundance for solid samples, whereas a 5 vol% CO 2 -standard gas is calibrated to allow delta values to be quoted against the Vienna-Pee-Dee Belemnite standard (Barrie et al, 1989; Coplen, 1996) . The data were expressed either as enrichment d 13 C and d 15 N over baseline (DOB), as atom percent excess (APE), as parts per million excess (ppm excess) (Slater et al, 2001) Orocaecal transit time. The orocaecal transit time (OCTT) was calculated from the time interval between raffinose intake and the detection of a significant and sustained rise of H 2 in breath of 10 ppm over baseline (ppmob) or more (Wutzke et al, 1997) .
Results
All results are quoted as mean7s.d.
Yield of dlLa1
The yield of bacterial wet mass was 5.2472.7 g/l, (n ¼ 5) Lactobacillus broth and the total of grown lactobacilli amounted to 2.972.5 Â 10 8 (n ¼ 5) CFU/ml broth. The determination of germ total by using the plate dilution technique showed a mixture of approximately 95% viable and 5% dead cells, respectively. The Breath H 2 -signals were observed in the expired air of 10 subjects beginning 3.0 h after raffinose administration. The maximum H 2 -concentration of 49 ppmob was reached after 5 h and was still detectable after 8 h (Figure 1 ). According to our definition, the measured OCTT was 3.770.8 h (Figure 1 ).
13
CO 2 -signals were observed in breath beginning 30 min after dlLa1 ingestion. The maximum 13 CO 2 -enrichment of 4.1 DOB was reached after 2.5 h and was still detectable after 14 h (Figure 2 ). The percentage cumulative 13 C-dose recovery amounted to 8.674.1 % of ingested dose (Figure 2 ). Figure 3 shows the 15 N-enrichment in urinary total-nitrogen (N) and ammonia. The mean maximum total-15 N-enrichment of 0.16 APE was reached after 4 h, whereas the mean 15 N-ammonia enrichment of 0.24 APE was already reached after 2.0 h.
Urine and faeces
The urinary PCE shows that 1.370.8 and 12.475.6% of ingested dose of 13 C and 15 N, respectively, were excreted 48 h after dlLa1 administration.
The faecal 13 C-and 15 N-excretion amounted to 39.9712.4% and 37.678.6% of ingested dose, respectively, 2 days after dlLa1 ingestion. Thus, 50% of the ingested dose of both labels are excreted in breath, urine and faeces. The numbers of La1 CFU/g in wet faeces were not counted.
Blood plasma fractions
The measured 13 C-and 15 N-excess-enrichments amounted to 0.17570.02 APE 15 N in supernatant, 70710 and 90760 ppm excess, respectively, in fibrinogen and 10710 and 60730 ppm excess, respectively, in plasma protein precipitates. Owing to the isotopic dilution with citrate carbon, the 13 C-enrichment of the supernatant was not measured.
Discussion
The human GIT contains a large number of bacteria, known as the gut microbiota, which are important either for health or diseases of the host. Probiotics are bacteria that, when consumed, have beneficial effects. They include L. johnsonii (La1), a bacterium of the acidophilus group of intestinal lactobacilli that strongly adheres to the mucosa. The probiotic La1 is added to yoghurts after preparation. La1 rivals with certain pathogens that may cause disease, thereby keeping them out of the GIT. At present, it is commonly accepted that La1 would first have to survive their journey through the intestine. During this passage, La1 are exposed to the acidic conditions of the stomach, followed by the hydrolytic enzymes and bile salts of the small intestine (Meydani & Ha, 2000) . Approximately 0.01-2% of yogurt bacteria such as La1 can survive the passage via the GIT (Meydani & Ha, 2000) and are then found in the faeces (Robins-Browne & Levine, 1981) .
In the present study, we used the stable isotope technique to follow the metabolic fate of viable dlLa1 during the passage through the human intestine in correlation to the OCTT.
When quantifying the OCTT, the lactulose hydrogen (H 2 )-breath test is the most widespread conventional method (King & Toskes, 1986; Sarno et al, 1993) . In 1995, our Rostock working group established an alternative 13 CO 2 -breath test method using lactose-[
13 C]ureide as a noninvasive marker for the evaluation of OCTT Wutzke et al, 1997; Wutzke & Glasenapp, 2004) . However, due to 13 C-interferences of lactose-[ 13 C]ureide and 13 C-labelled dlLa1 when administered simultaneously, the H 2 -breath test with raffinose was used for measuring the OCTT (Heine et al, 1996) in the present study. Our Research Laboratory has long-time experience in 15 N-labelling and in using yeast protein for tracer kinetic studies in humans (Wutzke et al, 1983 (Wutzke et al, , 1884 . To our knowledge, the combined use of a 15 N-labelled yeast extract and universal
13
C-labelled glucose for doubly labelling La1 has not been described so far (Table 1) .
The dlLa1 cells and raffinose were given simultaneously during breakfast to represent the transit of the meal. Furthermore, the dlLa1 was ingested together with unlabelled LC1 yoghurt to obtain a better distribution in the meal.
When considering the results obtained after dlLa1 and raffinose ingestion the differences of 13 CO 2 and H 2 increase in breath become obvious, in comparison to the prompt increase of 13 CO 2 0.5 h after dlLa1 administration, the H 2 onset appears approximately 3.2 h later, clearly indicating that the majority of dlLa1 is rapidly killed, degraded and absorbed in the small bowel before reaching the caecum (Figures 1 and 2 ). The corresponding prompt 15 N-enrichments 0.5 h after dlLa1 administration in urinary total-N, and, especially in ammonia, confirm this ( Figure 3 ). Another interesting result is the observed discrepancy between the cumulative excretion of both isotopes in urine: most of the 15 N is excreted in urine (12.4% of ingested dose), presumably as 15 N-urea as the main protein degradation product and as 15 N-ammonia minor amounts; however, most of the 13 C (8.6% of ingested dose) is exhaled as 13 CO 2 as the final end product of carbon metabolism. In comparison to the 15 Nexcretion in urine, the resulting sum of expiratory (8.6%) and renal 13 C-elimination (1.3%) of 9.3% of ingested dose is approximately in the same order of magnitude. The renal 13 C-excretion products are mainly urea and bicarbonate.
Other 13 C-labelled dlLa1 degradation products such as amino acids, carbohydrates and fat may be finally excreted as methane, or may be retained in the body bicarbonate pool or in other metabolic pathways. Figure 2 shows that 14 h after dlLa1 ingestion the 13 CO 2 -enrichment has not reached the baseline level indicating that additional 13 CO 2 will be exhaled over time. It can be assumed that a part of the 13 CO 2 is trapped in the large bicarbonate pool of the human body. Therefore, the delayed 13 CO 2 -exhalation leads to an underestimation of the excreted 13 C label and to an overestimation of the incorporated 13 C label, respectively. Our combination of measuring the expiratory, urinary and faecal excretion of 13 C-and 15 N-labeled metabolic degradation products of dlLa1 in correlation to the OCTT is a novelty. After oral ingestion of 15 N-labelled bifidobacteria in infants we observed similar results. The renal and faecal 15 N-excretion ranged between 9.2-17. 4% and 10.8-19 .6% of ingested dose, respectively .
The 13 C-and 15 N-enrichments of the blood plasma fractions evidenced that both stable isotopes were incorporated in the metabolic pool 2 h after dlLa1 ingestion. In comparison to the plasma protein precipitates, higher N-comparison showed that approximately equal amounts of both stable isotopes were excreted in faeces presumably as undigested dlLa1 or as nonabsorbable degradation products. When including the urinary and expiratory elimination, the ingestion of dlLa1 in healthy adults led to a total excretion of both stable isotopes of approximately 50% of ingested dose. A substantial portion of ingested dlLa1 is rapidly digested in the small intestine. The metabolites are incorporated into human tissue. In the current study, it was not possible to determine the proportion of viable organisms remaining in the colon. We hope that our findings will contribute to the understanding of the survival, digestion and elimination of La1 when consumed by humans.
